Absence of antiretroviral therapy and other risk factors for morbidity and mortality in Malaysian compulsory drug detention and rehabilitation centers.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 3445567)

Published in PLoS One on September 18, 2012

Authors

Jeannia J Fu1, Alexander R Bazazi, Frederick L Altice, Mahmood N Mohamed, Adeeba Kamarulzaman

Author Affiliations

1: Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, United States of America.

Articles citing this

Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13

The diagnostic performance of a single GeneXpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in Malaysia. PLoS One (2013) 1.06

An exploratory qualitative assessment of self-reported treatment outcomes and satisfaction among patients accessing an innovative voluntary drug treatment centre in Malaysia. Int J Drug Policy (2014) 0.91

Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health (2014) 0.87

Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia. J Subst Abuse Treat (2015) 0.85

HIV Prevalence Among People Who Inject Drugs in Greater Kuala Lumpur Recruited Using Respondent-Driven Sampling. AIDS Behav (2015) 0.83

Tuberculosis screening in a novel substance abuse treatment center in Malaysia: implications for a comprehensive approach for integrated care. J Subst Abuse Treat (2013) 0.83

Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from Malaysia. J Neuroimmune Pharmacol (2016) 0.80

Patterns of substance use and correlates of lifetime and active injection drug use among women in Malaysia. Am J Drug Alcohol Abuse (2015) 0.77

Pretreatment drug use characteristics and experiences among patients in a voluntary substance abuse treatment center in Malaysia: A mixed-methods approach. Subst Abus (2016) 0.77

Alcohol use disorders and antiretroviral therapy among prisoners in Argentina. Int J Prison Health (2013) 0.76

"Overconfidence" versus "helplessness": A qualitative study on abstinence self-efficacy of drug users in a male compulsory drug detention center in China. Subst Abuse Treat Prev Policy (2016) 0.75

HIV Testing and awareness of HIV status among people who inject drugs in greater Kuala Lumpur, Malaysia. AIDS Care (2017) 0.75

Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. Contemp Clin Trials (2017) 0.75

Articles cited by this

The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 76.04

HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02

Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet (2010) 5.02

An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med (2010) 4.24

Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet (2010) 3.29

Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. Int J Technol Assess Health Care (1995) 2.22

People who use drugs, HIV, and human rights. Lancet (2010) 2.09

Health and human rights concerns of drug users in detention in Guangxi Province, China. PLoS Med (2008) 2.06

Malaysia and harm reduction: the challenges and responses. Int J Drug Policy (2007) 1.49

Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia. Int J STD AIDS (2010) 1.40

Risk factors for HIV seropositivity in a sample of drug users in drug treatment in Ho Chi Minh City, Vietnam. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.30

The social context of HIV risk behaviour by drug injectors in Ho Chi Minh City, Vietnam. AIDS Care (2000) 1.28

Impact of HIV prevention programs on drug users in Malaysia. J Acquir Immune Defic Syndr (2009) 1.21

Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr (2010) 1.12

Use of the Mini International Neuropsychiatric Interview (MINI) as a screening tool in prisons: results of a preliminary study. J Am Acad Psychiatry Law (2004) 1.05

Preventing relapse in incarcerated drug users in Yunnan Province, China. Drug Alcohol Rev (2009) 0.91

Prevalence of thiamine deficiency at a drug rehabilitation centre in Malaysia. Med J Malaysia (2006) 0.87

"Patients, not criminals"? An assessment of Thailand's compulsory drug dependence treatment system. HIV AIDS Policy Law Rev (2009) 0.83

Human rights abuses, ethics, and the protection of subjects when conducting research on intravenous drug users in China. J Acquir Immune Defic Syndr (2011) 0.79

Prevalence of sexually transmitted diseases among female drug abusers in Malaysia. Med J Malaysia (1993) 0.79

Articles by these authors

Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med (2012) 7.04

Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis (2004) 6.27

Effect of Ebola progression on transmission and control in Liberia. Ann Intern Med (2014) 3.96

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet (2010) 3.90

The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18

Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89

Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol (2010) 2.50

High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother (2004) 2.41

A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend (2010) 2.38

Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet (2010) 2.26

Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis (2011) 2.12

Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health (Larchmt) (2011) 2.10

HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis (2011) 2.08

Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol (2008) 2.07

Identification of a novel circulating recombinant form (CRF33_01B) disseminating widely among various risk populations in Kuala Lumpur, Malaysia. J Acquir Immune Defic Syndr (2006) 1.97

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol (2010) 1.76

Multiple systemic embolisms with septicemia after gastric variceal obliteration with cyanoacrylate. Gastrointest Endosc (2002) 1.76

Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep (2005) 1.76

Health care-associated native valve endocarditis: importance of non-nosocomial acquisition. Ann Intern Med (2009) 1.76

Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73

Emerging HIV epidemics in Muslim countries: assessment of different cultural responses to harm reduction and implications for HIV control. Curr HIV/AIDS Rep (2007) 1.70

Identification of a novel second-generation circulating recombinant form (CRF48_01B) in Malaysia: a descendant of the previously identified CRF33_01B. J Acquir Immune Defic Syndr (2010) 1.69

Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study. Soc Sci Med (2002) 1.66

Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health (2010) 1.66

Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65

Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS (2007) 1.60

Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis (2006) 1.55

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS (2011) 1.52

TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease. AIDS (2011) 1.51

Malaysia and harm reduction: the challenges and responses. Int J Drug Policy (2007) 1.49

Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: the LifeWindows Project. AIDS Behav (2011) 1.49

HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse (2010) 1.48

Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. J Acquir Immune Defic Syndr (2010) 1.47

Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag (2009) 1.44

HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Int J Drug Policy (2007) 1.40

Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials (2007) 1.39

Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav (2013) 1.39

A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep (2012) 1.37

Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One (2012) 1.37

Understanding the revolving door: individual and structural-level predictors of recidivism among individuals with HIV leaving jail. AIDS Behav (2013) 1.35

Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr (2006) 1.33

Routine opt-out HIV testing strategies in a female jail setting: a prospective controlled trial. PLoS One (2009) 1.33

Adherence to HIV treatment and care among previously homeless jail detainees. AIDS Behav (2013) 1.33

Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ (2013) 1.33

A prospective controlled trial of routine opt-out HIV testing in a men's jail. PLoS One (2009) 1.32

Strategies for primary HIV prevention that target behavioral change. Clin Infect Dis (2007) 1.31

HIV control efforts should directly address incarceration. Lancet Infect Dis (2007) 1.31

Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care (2011) 1.31

Clinical care of the HIV-infected drug user. Infect Dis Clin North Am (2007) 1.30

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis (2012) 1.30

Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav (2010) 1.29

Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr (2009) 1.29

Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis (2008) 1.26

HIV-related research in correctional populations: now is the time. Curr HIV/AIDS Rep (2011) 1.25

Genome sequence of a novel HIV-1 circulating recombinant form 54_01B from Malaysia. J Virol (2012) 1.25

Optimizing care for HIV-infected people who use drugs: evidence-based approaches to overcoming healthcare disparities. Clin Infect Dis (2013) 1.24

Persistent immune activation in chronic HIV infection: do any interventions work? AIDS (2013) 1.24

Genome sequences of a novel HIV-1 CRF53_01B identified in Malaysia. J Virol (2012) 1.23

The impact of needle exchange-based health services on emergency department use. J Gen Intern Med (2002) 1.22

Adaptation of an evidence-based intervention targeting HIV-infected prisoners transitioning to the community: the process and outcome of formative research for the Positive Living Using Safety (PLUS) intervention. AIDS Patient Care STDS (2009) 1.22

Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology (2013) 1.19

Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health (2009) 1.18

Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr (2009) 1.16

Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend (2013) 1.15

Early identification of HIV: empirical support for jail-based screening. PLoS One (2012) 1.15

Gender disparities in HIV treatment outcomes following release from jail: results from a multicenter study. Am J Public Health (2014) 1.15

Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13

Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis (2009) 1.12

Emergency department use by released prisoners with HIV: an observational longitudinal study. PLoS One (2012) 1.11

Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav (2007) 1.11

Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr (2011) 1.10

Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS Behav (2013) 1.09

Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09

Estimating the date of origin of an HIV-1 circulating recombinant form. Virology (2009) 1.09

Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend (2011) 1.09

Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr (2011) 1.09

The association between history of violence and HIV risk: a cross-sectional study of HIV-negative incarcerated women in Connecticut. Womens Health Issues (2007) 1.08

Patterns of homelessness and implications for HIV health after release from jail. AIDS Behav (2013) 1.07

Testing an optimized community-based human immunodeficiency virus (HIV) risk reduction and antiretroviral adherence intervention for HIV-infected injection drug users. Subst Abus (2011) 1.06

The diagnostic performance of a single GeneXpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in Malaysia. PLoS One (2013) 1.06

Complex patterns of the HIV-1 epidemic in Kuala Lumpur, Malaysia: evidence for expansion of circulating recombinant form CRF33_01B and detection of multiple other recombinants. Virology (2007) 1.04

Tuberculin skin testing among healthcare workers in the University of Malaya Medical Centre, Kuala Lumpur, Malaysia. Infect Control Hosp Epidemiol (2002) 1.04

At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine. Addiction (2013) 1.04

Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc (2009) 1.04

Chronology of the HIV-1 CRF07_BC expansion in East Asia. AIDS (2008) 1.03

HIV testing in correctional institutions: evaluating existing strategies, setting new standards. AIDS Public Policy J (2007) 1.03

Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia. Am J Drug Alcohol Abuse (2010) 1.03

Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend (2013) 1.03

Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr (2011) 1.02

Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse (2007) 1.02

Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse (2009) 1.02

Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav (2013) 1.02